Shionogi & Co. Ltd., of Osaka, Japan, said cefiderocol (S-649266), a siderophore cephalosporin in late-stage development, met the FDA pre-specified primary endpoint for noninferiority vs. imipenem/cilastatin (IPM/CS) in patients with serious complicated urinary tract infection (cUTI) with gram-negative bacteria. Cefiderocol was superior to IPM/CS at test of cure (TOC).